Ensol Biosciences Inc. – Trademark Portfolio

Entity Type: 03

Ensol Biosciences Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ENTM. The owner is based in Daejeon.

51, Techno 10-ro, Yuseong-gu

Daejeon 34036 , KR

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ENTM
ENTM
Registered 2021
ENTM
ENTM
Registered 2021

Trademark Classifications

Ensol Biosciences Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Ensol Biosciences Inc. have?

Ensol Biosciences Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Ensol Biosciences Inc. file in?

Ensol Biosciences Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are Ensol Biosciences Inc.'s most well-known trademarks?

Ensol Biosciences Inc.'s registered trademark portfolio includes well-known marks such as ENTM. These are among 2 currently registered trademarks in the portfolio.

What is Ensol Biosciences Inc.'s trademark registration success rate?

Ensol Biosciences Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.